Bristol spinout Vitamica has closed a seed round with the backing of University of Bristol Enterprise Fund II and Wyvern Seed Fund.
Vitamica, UK-based antibiotic diagnostics spinout of University of Bristol, closed a seed round of undisclosed size on Monday backed by the University of Bristol Enterprise Fund (UBEF) II, managed by Parkwalk Advisors.
Wyvern Seed Fund and assorted angel investors also contributed to the round. UBEF II’s involvement had already been announced last month.
Founded in January 2018, Vitamica is developing a rapid diagnostic test to evaluate whether bacteria are susceptible to specific antibiotics. The technology aims to slow the rise of antimicrobial resistance that threatens to make treatments against infections ineffective.
The spinout advances research led by Massimo Antognozzi. The money will enable Vitamica to drive the further development of its prototype and to expand validation trials.
Paul Meakin, chief executive of Vitamica, said: “The seed investment will make a big difference in the speed and scale of our testing programme. We are extremely grateful for the support of the University of Bristol Enterprise Fund, managed by Parkwalk, Wyvern Seed Fund and a group of individual investors.
“In what has been an exciting process we have been assisted greatly by the University of Bristol Research and Enterprise team, and by VWV in finalising the legal documents.”